1	Elevated levels of IL-6 in IgA nephropathy patients are induced by an
2	epigenetically-driven mechanism triggered by viral and bacterial RNA
3	
4	Sallustio Fabio <sup>1</sup> , Claudia Curci <sup>2</sup> , Maria Teresa Cimmarusti <sup>2</sup> , Angela Picerno <sup>1</sup> , Giuseppe De Palma <sup>3</sup> ,
5	Carmen Sivo <sup>2</sup> , Francesca Annese <sup>2</sup> , Giulia Fontò <sup>2</sup> , Alessandra Stasi <sup>2</sup> , Francesco Pesce <sup>2</sup> , Vincenzo Di
6	Leo <sup>2</sup> , Loreto Gesualdo <sup>2</sup> .
7	
8	1) Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy
9	2) Nephrology, Dialysis and Transplantation Unit, DETO, University "Aldo Moro" Bari, Italy
10	3) Institutional Biobank, Experimental Oncology and Biobank Management Unit, Istituto di Ricovero e Cura
11	a Carattere Scientifico (IRCCS) Istituto Tumori Bari Giovanni Paolo II, Bari, Italy.
12	
13	
14	Corresponding author:
15	Fabio Sallustio, PhD; Department of Interdisciplinary Medicine, University of Bari "Aldo Moro",
16	Piazza G. Cesare,11 70124 Bari, Italy; Tel./ Fax: 0039 080 5478878; Email:
17	fabio.sallustio@uniba.it
18	

19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 20 ABSTRACT

Recently, a several models has been proposed to describe the pathogenesis of Immunoglobulin A nephropathy (IgAN), and among them the multihit and the gut-microbiota. These models explain the pathogenesis of IgAN caused by the production of aberrant IgA, but it is believed further predisposing factors are present, including immunological, genetic, environmental, or nutritional factors that can influence the pathogenesis and that could be useful for development of precision nephrology and personalized therapy.

27 Newly, the role of IL-6 in pathogenesis is becoming increasingly important. It is essential for

28 glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient

29 mice, even if the reason why levels of IL-6 are elevated in IgAN patients is not well understood.

30 One attainable hypothesis on high levels of IL-6 in IgAN comes out from our recent whole genome

31 DNA methylation screening in IgAN patients, that identified, among others, a hypermethylated

32 region comprising Vault RNA 2-1 (VTRNA2-1), a non-coding RNA also known as precursor of

miR-886 (pre-mi-RNA). Consistently, the VTRNA2-1 expression was found down-regulated in
 IgAN patients.

35

36 Here we confirm that VTRNA2-1 is low expressed in IgAN subjects compared to HS and we found 37 that also in transplanted IgAN patients (TP-IgAN), compared to non IgAN transplanted patients 38 (TP), the VTRNA2-1 transcript was expressed at level very low. We found that in IgAN patients 39 with downregulated VTRNA2-1, PKR is overactivated, coherently with the role of the VTRNA2-1 40 that binds to PKR and inhibits its phosphorylation. The loss of the VTRNA2-1 natural restrain 41 causes, in turn, the activation of CREB by PKR. We found CREB, a classical cAMP-inducible 42 CRE-binding factor interacting with a region of the IL-6 promoter and leading to IL-6 production, 43 overactivated both in IgAN and in TP-IgAN patients. Effectively, in the same patients, we found 44 elevated levels of IL-6 correlating with CREB and PKR phosphorylation.

45 Since PKR is normally activated by bacterial and viral RNA we hypothesized that these 46 microrganisms can further activate the PKR/CREB/IL-6 pathway leading to an excess of IL-6 47 production, explaining both the high levels of IL-6, both infection involvement in the disease, both 48 cases of IgAN associated with COVID-19 infection and with COVID-19 RNA-vaccination, and 49 recent data showing microbiota involvment in IgAN. 50 Effectively, we found that Effectively, we sfound that both the RNA poly(I:C) and the COVID-19 51 RNA-vaccine stimulation significantly increase the IL-6 levels in IgAN patient PBMCs. 52 The PKR/CREB/IL-6 pathway may be very important also in the setting of renal transplantation. 53 We found that this pathway is upregulated also in IgAN transplanted patients. Recent studies 54 showed that the cumulative risk of IgA nephropathy recurrence increases after transplant and is 55 associated with a 3.7-fold greater risk of graft loss. Finally, we showed that the IL-6 secretion can 56 be reduced by the PKR inhibitor imoxin.

57

In conclusion, the discovery of the upregulated VTRNA2-1/PKR/CREB/IL-6 pathway in IgAN patients may provide novel approach to treat the disease and may be useful for development of precision nephrology and personalized therapy, possibly by checking the VTRNA2-1 methylation level in IgAN patients.

62

63

#### 65 INTRODUCTION

Immunoglobulin A nephropathy (IgAN), also known as Berger's disease, is the most frequent primary glomerulonephritis characterized by the presence of IgA immune complexes in the glomeruli (1). It generally appears in the second and third decade of life, has a higher incidence in males and it is more common in whites than in blacks with a higher prevalence in Asians than Caucasians(1).

70 Recently, a multihit model has been proposed to describe the pathogenesis of IgAN. In this model,

71 the first hit is given by the hypersecretion of deglycosylated IgA (Gd-IgA1)(2). In circulation, these

72 Gd-IgA1 are recognized and attacked by autoantibodies (second hit) and this process leads to the

73 formation of circulating immune complexes (third hit), some of which are deposited at the mesangial

74 level in the glomeruli(2). Kidney damage resulting from the deposition of the cells is characterized

75 by local inflammation, complement activation, cell proliferation, and finally fibrosis(3).

Moreover, in humans, the gut-associated lymphoid tissue (GALT) is the primary source of IgA, so the pathogenesis of IgAN is related to gut homeostasis. Indeed, the intestinal–renal axis is important in Berger's glomerulonephritis, where several factors (e.g. genetics(4,5), infections(6,7), and food antigens (8) may play a role in the disease complex pathogenesis and provide novel therapeutic targets to modify disease evolution.

81

These models explain the pathogenesis of IgAN caused by the production of aberrant IgA, but it is believed further predisposing factors are present, including immunological, genetic, environmental, or nutritional factors that can influence the pathogenesis and that could be useful for development of precision nephrology and personalized therapy.

We have recently showed that IgAN patients have a higher frequency of intestinal-activated B cells
than healthy subjects (HS). IgAN patients had greater BAFF cytokine blood levels, which were linked
to higher levels of five microbiota metabolites, and high APRIL cytokine serum levels. In comparison
to HS, IgAN individuals had a larger number of circulating gut-homing (CCR9 β7 integrin) regulatory
B cells, memory B cells, and IgA memory B cells(9).

91 Moreover, several studies have shown the involvement of the IL-6 pathway in IgAN. Interleukin-6 is 92 essential for glomerular immunoglobulin A deposition and the development of renal pathology in 93 Cd37-deficient mice (10), Moreover, the proliferation-inducing ligand (APRIL) and IL-6 are 94 involved in the overproduction of aberrantly glycosylated IgA. In mice, the APRIL silencing blocked 95 the overproduction of Gd-IgA1 induced by IL-6 and, conversely, neutralizing IL-6, the production of 96 Gd-IgA1 was reduced(11). Interestingly, the mycotoxins deoxynivalenol (DON) prolonged exposure 97 cause the expansion of IgA secreting B cells by activating macrophages and T cells. In mice it results 98 in the early stages of human IgA nephropathy(12,13) and the overproduction of inflammatory 99 interleukins such as IL-6(14), which in turn induces upregulation of IgA.

100

However, to date, the biological mechanisms leading to the elevate IL6 levels in IgAN patients are
not clear. In a recent study, a whole-genome screening was performed for DNA methylation in CD4<sup>+</sup>
T cells from IgAN patients, identifying three regions with altered methylation capable of influencing
the gene expression of genes involved in cell response and proliferation T CD4<sup>+</sup>(15). In particular, a
hypermethylated region was identified comprising Vault RNA 2-1 (VTRNA2-1), a non-coding RNA
also known as the precursor of miR-886 (Pre-mi-RNA).

107

Here we studied the VTRNA2-1/PKR/CREB/IL-6 pathway showing that it is upregulated in IgAN patients and that it is responsible for the elevated IL-6 levels characterizing the disease, thus providing for the first time an explanation on the abnormal levels of this cytokine. We found that this pathway is epigenetically controlled by VTRNA2-1 and triggered by bacterial and viral infections. It can explain both the high levels of IL-6 both the correlation to mucosal infections of the disease. Finally, we showed how the imoxin inhibitor, targeting this pathway, can reduce IL-6 secretion by PBMCs of IgAN patients providing a new possible approach to treat the disease.

- 115
- 116

#### 117 **RESULTS**

118

#### 119 VTRNA2-1 is downregulated in IgAN patients

Recently, we showed that the non-coding RNA VTRNA2-1 was epigenetically downregulated in IgAN patients(15). Since we hypothesize that it may be implicated in the pathway for the secretion of IL-6, we further confirm the involvement of VTRNA2-1 in IgAN studying its expression in PBMCs isolated from IgAN patients and healthy subjects.

124 VTRNA2-1 was strongly downregulated in IgAN patients compared to healthy subjects showing a

decrease of 30 fold (p <0.05, Figure 1A). Moreover, recent clinical observations have shown that IL-

126 6 production is implicated in renal allograft rejection(16,17) and that cumulative risk of IgA

- 127 nephropathy recurrence increased after transplant and was associated with a 3.7-fold greater risk of
- 128 graft loss (17).

129 We therefore analysed the expression of VTRNA2-1 in PBMCs isolated from IgAN patients with

130 kidney transplant (T-IgAN) and in patients non-IgAN with kidney transplant (TP). Also in this case,

131 we found that the VTRNA2-1 was extremely downregulated in transplanted IgAN patients compared

132 to their controls (p<0.0001, fold change=100; Figure 1B), confirming that this modulation is a

133 characteristic of IgAN disease.





Figure 1. VTRNA2-1 expression in real-time PCR. (A)Real-time PCR of VTRNA2-1 transcript differentially
expressed in PBMCs of IgAN and HS. (B) Real-time PCR of VTRNA2-1 transcript differentially expressed in
PBMCs of T-IgAN and TP. Data are expressed as mean ± SEM, (\* p-value < 0.05, \*\*\*\*p-value <0.001).</li>

- 139
- 140

#### 141 Downregualtion of VTRNA2-1 In IgAN patients lead to the increase in phosphorilated PKR.

VTRNA2-1 can inhibit PKR, an interferon-inducible and double-stranded RNA (dsRNA) dependent kinase, by binding to this protein and preventing its auto-phosphorylation(18). Thus, we studied whether in the IgAN patients with low levels of VTRNA2-1 the correspective upregulation of the PKR signalling was present. We measured the levels of the phosphorilated (pPKR) and of the total PKR and found that in IgAN patients the level of pPKR protein normalized on the total PKR was significantly increased compared to HS (FC 2.6; p<0.05; Fig. 2A). At the same manner, also in T-IgAN we found the doubling of pPKR levels compared to TP (FC 2, p<0.05; Fig. 2B).

To confirm that the incerase in pPKR levels was due to the auto-phosphorylation induced by the lack of VTRNA2-1 and not by a different mechanism regulating the gene expression, we checked the PKR mRNA levels in IgAN patients and in HS. We found no significant differences between the two group

152 (Figure 2C). However, in T-IgAN compared to TP we found rather a decrease of the PKR transcripts







#### 155 Figure 2. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated PKR

(A) ELISA assay showed significantly increased level of phosphorylated PKR in IgAN patients respect to healthy
group (HS). (B) A strong increase in phospho-PKR levels was found in T-IgAN patients compared to TP group. (C)
Gene expression of PKR in IgAN patients and HS. (D) Gene expression of PKR in TP and T-IgAN patients. Data
are representative of 8 independent experiments (means ±SEM; \* p-value < 0.05).</li>

- 160
- 161

#### 162 Phosphorilation of PKR corresponds to CREB activation in IgAN patients

In mice pPKR induced the Cyclic adenosine monophosphate (AMP) response element-binding protein (CREB) activation by increasing its phosphorilation (12). We studied whether in IgAN patients CREB phosphorilation levels were higher compared to HS. A significant 3-fold increase of pCREB levels was found in IgAN patients compared to HS (p<0.01; Fig. 3 A). Also in T-IgAN pCREB levels were significantly increase compared to TP, even if to less extent (1.67 fold, p<0.01; Fig. 3B). However, no significant difference in CREB gene expression was present among IgAN

169 patients and HS (Figure 3C), nor in TX compared to T-IgAN (Fig. 3D), corroborating the data of







Figure 3. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated CREB (A) The assay
revealed systemic activation of CREB (phospho-Thr305-CREB) in IgAN group compared to healthy subjects (HS).
(B) CREB phosphorylation was also significantly increased in T-IgAN patients compared to transplanted patients
without IgAN disease. (C) Gene expression of CREB in IgAN patients and HS. (D) Gene expression of CREB in
TP and T-IgAN patients. Data are representative of 8 independent experiments (means ±SEM; \* p-value < 0.05,</li>
\*\*\*\*p-value <0.001).</li>

178

#### 179 CREB activation by phosphorilation leads to IL-6 incerase in IgAN patients.

Since several studies showed that CREB activation may lead to IL-6 expression(20–24), we analyzed the IL-6 levels secreted by PBMCs in our IgAN patient groups. IL-6 levels showed a statistically significant increase in IgAN patients compared to HS (p<0.05; Fig. 4A). In T-IgAN compared to TP a tendence in increased levels of IL-6 was found, even if it is not significant (Fig. 4B). Both the levels of pCREB and pPKR significantly correlated with IL-6 levels in IgAN patients (r=0.97, p=0.0006

and r=0.89, p=0.0064, respectively), indicating that the high levels of this cytokine are due to the

186 VTRNA2-1/pPKR/pCREB signalling epigenetically regulated (Figure 4C-D).

187





189

190Figure 4. VTRNA2-1/PKR/CREB activated pathway leads to elevated IL-6 secretion in IgAN patients (A)191ELISA assay showed significant increased levels of IL-6 in IgAN patients with VTRNA2-1/PKR/CREB activated192pathway respect to healthy group. (B) An IL-6 increase was found in T-IgAN patients with VTRNA2-1/PKR/CREB193activated pathway compared to TP group, even if not statistically significant. Both the levels of pPKR (C) and194pCREB (D) significantly correlated with IL-6 levels in IgAN patients ( r=0.97, p= 0.0006 and r=0.89, p=0.0064,195respectively). Data are representative of 8 independent experiments (means ±SEM; \* p-value < 0.05).</td>

196

197

### 199 Bacterial RNA viral RNA or COVID vaccine stimulation increase and imoxin decrease IL-6

#### 200 secretion by PBMCs from HS and IgAN patients.

The biological effect of triggering or blocking the PKR/CREB/IL-6 pathway on PBMCs from IgAN patients and HS was studied. Since PKR can be activated by viral or bacterial RNA (25,26) (27,28) lymphocytes were transfected with synthetic polyinosinic:polycytidylic acid (poly(I:C)), which mimics viral dsRNA or with a COVID RNA vaccine. We found that the poly(I:C) and the vaccine stimulation significantly increased the IL-6 secretion by PBMCs from both HS and IgAN patients (Figure 5, p<0.05).

We then studied the effect of the PKR inhibitor imoxin on the IL-6 secretion. When IgAN patients and HS PBMCs were stimulated with 1  $\mu$ M imoxin, a drastic decrease in IL-6 levels was obtained (Figure 6 A-B, p<0.05). Interestingly, Imoxin was effective also when used 48h after stimulation with poly(I:C) (Figure 6C).



#### 212 Figure 5. poly(I:C) and COVID vaccine stimulation increase and imoxin decrease IL-6 secretion by PBMCs

#### 213 from HS and IgAN patients.

- 214 ELISA assay showing that the poly(I:C) (A) and the COVID vaccine (B) stimulation significantly increased the IL-
- 215 6 secretion by PBMCs from HS. (C) ELISA assay showing that imoxin (C16) significantly decrease the IL-6
- 216 secretion by PBMCs from HS. (D) ELISA assay showing that imoxin (C16) significantly decrease the IL-6 secretion
- 217 by PBMCs from IgAN patients.
- 218



219

#### 220 Figure 6. PKR Inhibitor Imoxin decrease the IL-6 secretion even following viral RNA triggering

221 ELISA assay showing that imoxin (C16) significantly decrease the IL-6 secretion in PBMCS from HS, even when

222 used 48h after stimulation with poly(I:C).

#### 224 **DISCUSSION**

The exact immunopathogenic mechanisms underlying IgAN are poorly understood. The original multi-hit pathogenesis model integrates findings from studies on galactose-deficient IgA1, antiglycan response, formation, deposition of IgA1-containing immune complexes, and mechanisms of immune complex-mediated tissue injury. Very recently the role of Il-6 in IgAN pathogenesis is becoming increasingly important(29–33), even if the reason why levels of IL-6 are elevated in IgAN patients is not well understood.

It selectively increases production of galactose-deficient IgA1 in IgA1-secreting cells from patients with IgA nephropathy(29,30) and IL6-/- mice displayed no glomerular IgA deposition and were protected from exacerbated renal failure following lipopolysaccharide treatment(32). Interestingly, IL-6 signalling seems to be involved in this complex intestinal immune network particularly in mediating the production of Gd-IgA(10,34).

One attainable hypothesis on high levels of IL-6 in IgAN comes out from our recent whole genome DNA methylation screening in IgAN patients, that identified, among others, three regions with altered DNA methylation capable of influencing the expression of genes involved in the response and proliferation of T and B cells (15). We identified a hypermethylated region comprising Vault RNA 2-1 (VTRNA2-1), a non-coding RNA also known as precursor of miR-886 (pre-mi-RNA). Consistently, the VTRNA2-1 expression was found down-regulated in IgAN patients(15).

Here we confirm that VTRNA2-1 is lower expressed in IgAN subjects compared to HS and we found 242 243 that also in transplanted IgAN patients compared to non IgAN transplanted patients the VTRNA2-1 244 transcript was expressed at level very low. The VTRNA2-1 gene produces an RNA polymerase III 245 transcript that resembles both a component of the ribonucleoprotein vault particle and a pre-246 microRNA. However, the RNA product does not function as a vault or microRNA; rather, it acts as 247 a direct inhibitor of protein kinase R (also known as eukaryotic translation initiation factor 2-alpha 248 kinase 2, EIF2AK2), and thereby plays an important role in the regulation of cell growth. This gene is nearby a differentially methylated region (DMR), is imprinted and may show allele-specific 249

expression. VTRNA2-1 is a metastable epiallele with accumulating evidence that methylation at this region is heritable, modifiable, and associated with disease including risk and progression of cancer(35).

We found that, in IgAN patients with downregulated VTRNA2-1, PKR is overactivated, coherently with the role of the VTRNA2-1 that binds to PKR and inhibits its phosphorylation (36). The loss of this natural restrain causes the activation of CREB, a classical cAMP-inducible CRE-binding factor interacting with a region of the IL-6 promoter (that is known as CRE-like sequence), leading to IL-6 production (20–24).

258

259 The discovery of the upregulation of the PKR/CREB/IL-6 in IgAN patients is very suggestive. PKR 260 is normally activated by double-strand bacterial(25,26) and single-strand viral (27,28) RNA and has 261 long been recognized as a key mediator of the innate immunity response to viral infection. Expression 262 of latent PKR is induced by interferon and it is activated upon binding to viral RNA containing duplex 263 regions to undergo autophosphorylation. The data showing that, in IgAN patients, the PKR signalling 264 is already activated due to their epigenetic background could explain why the disease has traditionally 265 been considered as correlated to mucosal infections because of the clinical manifestation of hematuria 266 following upper respiratory tract microbes challenge(37,38). Bacterial and viral RNA may effectively 267 further activate the PKR/CREB/IL-6 pathway leading to an excess of IL-6 production.

Moreover, recently has been found that, upon stimulation in vitro, the Epstein-Barr virus (EBV)infected IgA+ B cells secreted Gd-IgA1 and that B cells and their IgA+ subpopulation in PBMCs of IgAN patients displayed a significantly higher frequency of EBV infection than did cells of the same phenotype from non-IgAN patients(39). Interestingly, a different study very recently showed that PKR is regulated by EBV RNA(40).

This kind of mechanism, driven by the epigenetic silencing of VTRNA2-1, may therefore explain both the high levels of IL-6, and infection involvement in the disease, and recent data showing microbiota involvment in IgAN (9) (41) (42). Our hypothesis is also supported by studies showing

276	that synthetic double-stranded RNA poly(I:C) stimulation promotes IgA class-switch recombination
277	and BAFF productions in tonsil mononuclear cells via the TLR3 pathway(43). Effectively, we
278	showed that both the RNA poly(I:C) and the COVID-19 RNA-vaccine stimulation significantly
279	increase the IL-6 levels in IgAN patient PBMCs.

Also, recent data showing 13 IgAN cases associated with COVID-19 infection and 4 cases of IgAN
following COVID-19 RNA-vaccination(44) may be clearly explained by our discovered mechanism

trough the PKR activation by RNA.

283

284 The PKR/CREB/IL-6 pathway may be very important also in the setting of renal transplantation. We 285 found that this pathway is upregulated also in IgAN transplanted patients. Recent studies showed that 286 the cumulative risk of IgA nephropathy recurrence increases after transplant and is associated with a 287 3.7-fold greater risk of graft loss(45). Besides, evidence suggests that IL-6 may play an important 288 role in donor-specific antibodies generation and chronic active antibody-mediated rejection and that 289 the treatment with an anti-IL-6 receptor monoclonal antibody may represent a novel approach for 290 chronic antibody-mediated rejection and transplant glomerulopathy, stabilizing allograft function and 291 extend patient lives (17).

292

293 Finally, we showed that the IL-6 secretion can be reduced by the PKR inhibitor imoxin. This drug 294 also known as C16 or imidazole, has shown beneficial effects on cell cultures and in vivo in animal 295 models for numerous conditions, such as improvement in inflammation, oxidative stress, diabetes, 296 suppression of tumor proliferation and in the control of hypertension. However, in light of our results, 297 it may be considered as a possible therapeutic drug also in IgAN (46). Interestingly, in mice dietary exposure to the common foodborne mycotoxin deoxynivalenol (DON) 298 upregulates serum 299 immunoglobulin A (IgA) and IL-6 miming IgAN and activating PKR/CREB/IL-6 pathway. The 300 dietary omega-3 fatty acids can invert these processes and ameliorate DON-induced IgA nephropathy 301 (12, 13).

2	02	
3	02	

303	In conclusion, the discovery of the upregulated VTRNA2-1/PKR/CREB/IL-6 pathway in IgAN
304	patients may provide novel approach to treat the disease and may be useful for development of
305	precision nephrology and personalized therapy, possibly by checking the VTRNA2-1 methylation
306	level in IgAN patients.
307	
200	
308	
309	
310	
311	
312	
313	
314	
315	
316	
317	
318	

#### 319 MATERIALS AND METHODS

320

#### 321 Study design and patients

The study was carried out in accordance with the Helsinki Declaration and the European Guidelines for Good Clinical Practice and approved by our institutional ethics review. A total of 15 biopsyproven IgAN patients, 22 IgAN subjects with kidney transplant (T-IgAN), 14 patients transplanted for causes other than IgAN (TP), and 10 Healthy subjects (HS) from south Italy were included in the study after providing their written informed consent.

PBMCs were isolated by gradient centrifugation with Ficoll-Hypaque (Euroclone, Italy) from
heparinized venous blood from patients and HS. PBMCs were cultured in RPMI 1640 (Euroclone)
supplemented with 10% Fetal Bovine Serum (Euroclone), 100U/mL Penicillin/Streptomycin
(Euroclone), 4mMGlutamine (Euroclone), 10 mM Hepes (Sigma), 0.1 mM non-essential amino acids
(Euroclone), 1mM sodium pyruvate and 50 U/mL, rhIL-2.

332

#### 333 RNA extraction and real time-PCR expression of VTRNA2-1, CREB and PKR

334Total RNA were isolated from PBMCs of IgAN, T-IgAN, TP and HS using RNeasy Mini Kit (Qiagen,

335 Hilden, Germany) according to the manufacturer's instruction and quantified by NanoDrop One

336 Spectrophotometer (thermoFisher Scientific). Total RNA was retro-transcribed using the miScript II

RT Kit with iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) following the manufacturer's
instructions.

Real Time-PCR was performed on a StepOne Plus instrument (Applied Biosystems) by using
VTRNA2-1, PKR and CREB primers (Integrated DNA Technologies, Coralville,

341 IA,USA) GAPDH gene amplification was used as a reference standard to normalize the target signal.

Real Time-PCR was performed in triplicate, and relative expression was calculated using the  $2-\Delta C_t$ method.

#### 345 pPKR/pCREB/IL-6 pathway ELISA quantification

- 346 Colorimetric Cell-Based ELISA assays were used to detect the levels of CREB/pCREB (CREB
- 347 (Phospho-Ser142) Aviva Systems Biology, USA), and PKR/pPKR (PKR (Phospho-Thr258) Aviva
- 348 Systems Biology, USA).
- 349 Briefly, PBMCs of HS, IgAN, T-IgAN and TP subjects were freshly isolated and seeded overnight
- 350 with RPMI medium at 37°C, 5% CO<sub>2</sub>, in a 96-Well Cell Culture Clear-Bottom Microplate. The
- 351 ELISA assay protocols were executed following manufacturer instructions.
- 352 To determine IL-6 levels, PBMCs of HS, IgAN, T-IgAN and TP subjects, were freshly isolated and
- 353 seeded in a 96-Well Cell Culture Microplate supplemented with RPMI medium at 37°C, 5% CO<sub>2</sub>.
- After 48 h of culture, cells were collected and, centrifuged at 230 rpm for 15 minutes. Supernatant
- 355 were recovered and analysed using Human IL-6 Quantikine ELISA Kit (R&D Systems, USA),
- 356 following manufacturer's protocol.
- 357 Optical densities were determined using a microplate reader (programmable MPT reader model DV
  358 990BV6; GDV, Italy) set to 450 nm.
- 359

#### 360 Transfection experiments

PBMCs of HS and IgAN patients were seeded in 6-well plates at a density of 2 x  $10^6$  cells/cm<sup>2</sup> and were incubated with specific medium. Xfect Transfection Reagent (Clontech, Takara bio, France) was used to transfect 20 ug of Poly (I:C) (InvivoGen, Europe), a synthetic analogue of dsRNA, in PBMC cells, according to manufacturer's instructions. Imoxin (Chem Cruz) was added to PBMCs at a concentration of 1  $\mu$ M. After two days of incubation with Poly (I:C) and/or Imoxin the secretion of IL-6 levels by PBMCs were measured in the cell culture supernatants.

367

#### 368 Statistical Analysis

369 Statistical analyses were performed using the Student's t-test, as appropriate. A p-value < 0.05 was

370 considered significant. Data are expressed as means  $\pm$  SEM.

#### 371 **REFERENCES**

372

- Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. *Clinical Journal of the American Society* of Nephrology (2017) 12:677–686. doi: 10.2215/CJN.07420716
   Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. *Clinical and*
- 376 *Experimental Nephrology 2018 23:1* (2018) **23**:26–31. doi: 10.1007/S10157-018-1582-2
- 377 3. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F,
- 378 Mestecky J, Gharavi AG, et al. The Pathophysiology of IgA Nephropathy. doi:
  379 10.1681/ASN.2011050464
- 380 4. Sallustio F, Cox SN, Serino G, Curci C, Pesce F, De Palma G, Papagianni A, Kirmizis D,
- 381 Falchi M, Schena FP. Genome-wide scan identifies a copy number variable region at 3p21.1

that influences the TLR9 expression levels in IgA nephropathy patients. *European Journal of* 

383 *Human Genetics 2015 23:7* (2014) **23**:940–948. doi: 10.1038/ejhg.2014.208

- 384 5. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan AK, Mizoguchi E, Geha RS. Impaired
- IgA class switching in APRIL-deficient mice. *Proceedings of the National Academy of Sciences* (2004) 101:3903–3908. doi: 10.1073/PNAS.0307348101
- 387 6. Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash
- 388 S, Shapiro S, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved
- in immunity against intestinal pathogens. *Nature Genetics 2014 46:11* (2014) 46:1187–1196.
  doi: 10.1038/ng.3118
- 391 7. Coppo R. The intestine-renal connection in IgA nephropathy. *Nephrology Dialysis* 392 *Transplantation* (2015) 30:360–366. doi: 10.1093/NDT/GFU343
- 393 8. Papista C, Lechner S, Mkaddem S Ben, LeStang M-B, Abbad L, Bex-Coudrat J, Pillebout E,
- 394 Chemouny JM, Jablonski M, Flamant M, et al. Gluten exacerbates IgA nephropathy in
- humanized mice through gliadin–CD89 interaction. *Kidney International* (2015) **88**:276–285.
- 396 doi: 10.1038/KI.2015.94

Sallustio F, Curci C, Chaoul N, Fontò G, Lauriero G, Picerno A, Divella C, di Leo V, de
 Angelis M, ben Mkaddem S, et al. High levels of gut-homing immunoglobulin A-positive+B
 lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in
 immunoglobulin A nephropathy patients. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* (2020) doi: 10.1093/ndt/gfaa264

- Rops ALWMM, Jansen E, van der Schaaf A, Pieterse E, Rother N, Hofstra J, Dijkman HBPM,
  van de Logt AE, Wetzels J, van der Vlag J, et al. Interleukin-6 is essential for glomerular
  immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.
- 406 *Kidney International* (2018) **93**:1356–1366. doi: 10.1016/J.KINT.2018.01.005
- Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation
  induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA
  nephropathy. *Kidney International* (2020) 97:340–349. doi: 10.1016/J.KINT.2019.08.022
- 410 12. Pestka JJ. Deoxynivalenol-induced IgA production and IgA nephropathy-aberrant mucosal
  411 immune response with systemic repercussions. *Toxicology Letters* (2003) 140–141:287–295.
- 412 doi: 10.1016/S0378-4274(03)00024-9
- 413 13. Shi Y, Pestka JJ. Mechanisms for suppression of interleukin-6 expression in peritoneal
  414 macrophages from docosahexaenoic acid-fed mice. *Journal of Nutritional Biochemistry* (2009)
- 415 **20**:358–368. doi: 10.1016/J.JNUTBIO.2008.04.006
- 416 14. Yan D, Zhou HR, Brooks KH, Pestka JJ. Potential role of IL-5 and IL-6 in enhanced IgA
  417 secretion by Peyer's patch cells isolated from mice acutely exposed to vomitoxin. *Toxicology*418 (1997) 122:145–158. doi: 10.1016/S0300-483X(97)00087-5
- 419 15. Sallustio F, Serino G, Cox SN, Gassa AD, Curci C, De Palma G, Banelli B, Zaza G, Romani
- 420 M, Schena FP. Aberrantly methylated DNA regions lead to low activation of CD4+ T-cells in
- 421 IgA nephropathy. *Clinical Science* (2016) **130**:733–746. doi: 10.1042/CS20150711

- 422 16. Kim I, Wu G, Chai N, Klein AS, Jordan S. Anti-interleukin 6 receptor antibodies attenuate
  423 antibody recall responses in a mouse model of allosensitization. *Transplantation* (2014)
  424 98:1262–70. doi: 10.1097/TP.00000000000437
- 425 17. Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, et
- 426 al. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential
- 427 Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-
- 428 Sensitized Renal Allograft Recipients. *American journal of transplantation : official journal*
- 429 of the American Society of Transplantation and the American Society of Transplant Surgeons
- 430 (2017) **17**:2381–2389. doi: 10.1111/ajt.14228
- 431 18. Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, Bang JY, Park HS, Leelayuwat
- C, Lee YS. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with
  PKR and modulates its activity. *RNA* (2011) 17:1076–1089. doi: 10.1261/rna.2701111
- 434 19. Shi Y, Pestka JJ. Mechanisms for suppression of interleukin-6 expression in peritoneal
  435 macrophages from docosahexaenoic acid-fed mice. *The Journal of nutritional biochemistry*436 (2009) 20:358–68. doi: 10.1016/j.jnutbio.2008.04.006
- 437 20. Spooren A, Kooijman R, Lintermans B, van Craenenbroeck K, Vermeulen L, Haegeman G,
- Gerlo S. Cooperation of NFkappaB and CREB to induce synergistic IL-6 expression in
  astrocytes. *Cellular signalling* (2010) 22:871–81. doi: 10.1016/j.cellsig.2010.01.018
- 440 21. Ishizu A, Abe A, Miyatake Y, Baba T, Iinuma C, Tomaru U, Yoshiki T. Cyclic AMP response
  441 element-binding protein is implicated in IL-6 production from arthritic synovial cells. *Modern*
- 442 *rheumatology* (2010) **20**:134–8. doi: 10.1007/s10165-009-0245-2
- 443 22. Yang R, Lin Q, Gao HB, Zhang P. Stress-related hormone norepinephrine induces interleukin-
- 444 6 expression in GES-1 cells. *Brazilian journal of medical and biological research = Revista*
- 445 brasileira de pesquisas medicas e biologicas (2014) 47:101–9. doi: 10.1590/1414-
- 446 431X20133346

-11 $-2.7$ $-2.00$ $-1.200$ $-1.200$ $-1.000$ $-0.000$ $-0.000$ $-0.000$ $-0.000$ $-0.000$ $-0.000$ $-0.000$	447	23.	Luo Y	Zheng SG.	. Hall of Fame among	Pro-inflammatory	V Cvtokines:	Interleukin-6 G	iene a
--	-----	-----	-------	-----------	----------------------	------------------	--------------	-----------------	--------

- Its Transcriptional Regulation Mechanisms. *Frontiers in Immunology* (2016) 7:604. doi:
  10.3389/fimmu.2016.00604
- 450 24. Dendorfer U, Oettgen P, Libermann TA. Multiple regulatory elements in the interleukin-6 gene
- 451 mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. *Molecular and*

452 *cellular biology* (1994) **14**:4443–54. doi: 10.1128/mcb.14.7.4443-4454.1994

453 25. Bleiblo F, Michael P, Brabant D, Ramana C v., Tai T, Saleh M, Parrillo JE, Kumar A, Kumar

454 A. Bacterial RNA induces myocyte cellular dysfunction through the activation of PKR.
455 *Journal of Thoracic Disease* (2012) 4: doi: 10.3978/J.ISSN.2072-1439.2012.01.07

- 456 26. Hull CM, Bevilacqua PC. Mechanistic Analysis of Activation of the Innate Immune Sensor
- 457 PKR by Bacterial RNA. Journal of molecular biology (2015) 427:3501–3515. doi:
  458 10.1016/j.jmb.2015.05.018
- 459 27. García MA, Meurs EF, Esteban M. The dsRNA protein kinase PKR: virus and cell control.
  460 *Biochimie* (2007) 89:799–811. doi: 10.1016/j.biochi.2007.03.001
- 461 28. Pindel A, Sadler A. The role of protein kinase R in the interferon response. Journal of
  462 interferon & cytokine research : the official journal of the International Society for Interferon
  463 and Cytokine Research (2011) 31:59–70. doi: 10.1089/jir.2010.0099
- Zhang J, Mi Y, Zhou R, Liu Z, Huang B, Guo R, Wang P, Lu Y, Zhou Y, Quan S. The TLR4MyD88-NF-κB pathway is involved in sIgA-mediated IgA nephropathy. *Journal of nephrology* (2020) 33:1251–1261. doi: 10.1007/s40620-020-00722-3
- 467 30. Yamada K, Huang Z-Q, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z,
- Kiryluk K, Suzuki Y, et al. Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen
  Production in IgA Nephropathy. *Kidney International Reports* (2017) 2:1194–1207. doi:
- 470 10.1016/j.ekir.2017.07.002

471	31.	Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation
472		induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA
473		nephropathy. Kidney International (2020) doi: 10.1016/j.kint.2019.08.022

- 474 32. Rops ALWMM, Jansen E, van der Schaaf A, Pieterse E, Rother N, Hofstra J, Dijkman HBPM,
- 475 van de Logt AE, Wetzels J, van der Vlag J, et al. Interleukin-6 is essential for glomerular
- 476 immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.

477 *Kidney International* (2018) **93**:1356–1366. doi: 10.1016/j.kint.2018.01.005

- 33. Si R, Zhao P, Yu Z, Qu Z, Sun W, Li T, Jiang Y. Increased Non-switched Memory B Cells are
  Associated with Plasmablasts, Serum IL-6 Levels and Renal Functional Impairments in IgAN
  Patients. *Immunological Investigations* (2020) doi: 10.1080/08820139.2019.1683026
- 481 34. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation
  482 induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA
  483 nephropathy. *Kidney International* (2020) 97:340–349. doi: 10.1016/J.KINT.2019.08.022

484 35. Dugué P-A, Yu C, McKay T, Wong EM, Joo JE, Tsimiklis H, Hammet F, Mahmoodi M, Theys

- 485 D, kConFab, et al. VTRNA2-1: Genetic Variation, Heritable Methylation and Disease
  486 Association. *International Journal of Molecular Sciences* (2021) 22:2535. doi:
  487 10.3390/ijms22052535
- Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang G-Y, Bang JY, Park HS, Leelayuwat
  C, Lee YS. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with
  PKR and modulates its activity. *RNA* (2011) 17:1076–1089. doi: 10.1261/RNA.2701111
- 491 37. He J-W, Zhou X-J, Lv J-C, Zhang H. Perspectives on how mucosal immune responses,
  492 infections and gut microbiome shape IgA nephropathy and future therapies. *Theranostics*493 (2020) 10:11462–11478. doi: 10.7150/thno.49778
- 494 38. Rollino C, Vischini G, Coppo R. IgA nephropathy and infections. *Journal of Nephrology*495 (2016) 29:463–468. doi: 10.1007/s40620-016-0265-x

- 496 39. Zachova K, Kosztyu P, Zadrazil J, Matousovic K, Vondrak K, Hubacek P, Julian BA,
- 497 Moldoveanu Z, Novak Z, Kostovcikova K, et al. Role of Epstein-Barr Virus in Pathogenesis
- 498 and Racial Distribution of IgA Nephropathy. *Frontiers in Immunology* (2020) **11**:267. doi:
- 499 10.3389/fimmu.2020.00267
- 500 40. Zerbe CM, Cole JL. Regulation of Protein Kinase R by Epstein-Barr Virus EBER1 RNA.
  501 *Biochemistry* (2020) **59**:1252–1260. doi: 10.1021/acs.biochem.0c00088
- He JW, Zhou XJ, Lv JC, Zhang H. Perspectives on how mucosal immune responses, infections
  and gut microbiome shape iga nephropathy and future therapies. *Theranostics* (2020)
  10:11462–11478. doi: 10.7150/THNO.49778
- Angelis M De, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, Gozzi G,
  Serrazanetti D, Dalfino G, Gobbetti M, et al. Microbiota and Metabolome Associated with
  Immunoglobulin A Nephropathy (IgAN). *PLOS ONE* (2014) 9:e99006. doi:
- 508 10.1371/JOURNAL.PONE.0099006
- He L, Peng X, Wang J, Tang C, Zhou X, Liu H, Liu F, Sun L, Peng Y. Synthetic doublestranded RNA Poly(I:C) aggravates IgA nephropathy by triggering IgA class switching
  recombination through the TLR3-BAFF axis. *American Journal of Nephrology* (2015)
  42:185–197. doi: 10.1159/000440819
- 513 44. Farooq H, Aemaz Ur Rehman M, Asmar A, Asif S, Mushtaq A, Qureshi MA. The pathogenesis
- of COVID-19-induced IgA nephropathy and IgA vasculitis: A systematic review. *Journal of Taibah University Medical Sciences* (2021) doi: 10.1016/j.jtumed.2021.08.012
- 516 45. Uffing A, Pérez-Saéz MJ, Jouve T, Bugnazet M, Malvezzi P, Muhsin SA, Lafargue M-C,
- 517 Reindl-Schwaighofer R, Morlock A, Oberbauer R, et al. Recurrence of IgA Nephropathy after
- 518 Kidney Transplantation in Adults. *Clinical journal of the American Society of Nephrology*:
- 519 *CJASN* (2021) **16**:1247–1255. doi: 10.2215/CJN.00910121

- 520 46. Kalra J, Dasari D, Bhat A, Mangali S, Goyal SG, Jadhav KB, Dhar A. PKR inhibitor imoxin
- 521 prevents hypertension, endothelial dysfunction and cardiac and vascular remodelling in L-
- 522 NAME-treated rats. *Life Sciences* (2020) **262**: doi: 10.1016/J.LFS.2020.118436

#### 531 FIGURE LEGENDS

532

Figure 1. VTRNA2-1 expression in real-time PCR. (A)Real-time PCR of VTRNA2-1 transcript differentially expressed in PBMCs of IgAN and HS. (B) Real-time PCR of VTRNA2-1 transcript differentially expressed in PBMCs of T-IgAN and TP. Data are expressed as mean  $\pm$  SEM, (\* p-value < 0.05, \*\*\*\*p-value <0.001).

537

#### 538 Figure 2. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated PKR

539 (A) ELISA assay showed significantly increased level of phosphorylated PKR in IgAN patients 540 respect to healthy group (HS). (B) A strong increase in phospho-PKR levels was found in T-IgAN 541 patients compared to TP group. (C) Gene expression of PKR in IgAN patients and HS. (D) Gene 542 expression of PKR in TP and T-IgAN patients. Data are representative of 8 independent experiments 543 (means  $\pm$ SEM; \* p-value < 0.05).

- 544
- 545

# Figure 3. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated CREB (A) The assay revealed systemic activation of CREB (phospho-Thr305-CREB) in IgAN group compared to healthy subjects (HS). (B) CREB phosphorylation was also significantly increased in T-IgAN patients compared to transplanted patients without IgAN disease. (C) Gene expression of CREB in IgAN patients and HS. (D) Gene expression of CREB in TP and T-IgAN patients. Data are representative of 8 independent experiments (means $\pm$ SEM; \* p-value < 0.05, \*\*\*\*p-value <0.001).

## 553 Figure 4. VTRNA2-1/PKR/CREB activated pathway leads to elevated IL-6 secretion in IgAN 554 patients (A) ELISA assay showed significant increased levels of IL-6 in IgAN patients with 555 VTRNA2-1/PKR/CREB activated pathway respect to healthy group. (B) An IL-6 increase was found 556 in T-IgAN patients with VTRNA2-1/PKR/CREB activated pathway compared to TP group, even if

557	not statistically significant. Both the levels of pPKR (C) and pCREB (D) significantly correlated with
558	IL-6 levels in IgAN patients ( r=0.97, p= 0.0006 and r=0.89, p=0.0064, respectively). Data are
559	representative of 8 independent experiments (means $\pm$ SEM; * p-value < 0.05).
560	
561	Figure 5. poly(I:C) and COVID vaccine stimulation increase and imoxin decrease IL-6
562	secretion by PBMCs from HS and IgAN patients.
563	ELISA assay showing that the poly(I:C) (A) and the COVID vaccine (B) stimulation significantly
564	increased the IL-6 secretion by PBMCs from HS. (C) ELISA assay showing that imoxin (C16)
565	significantly decrease the IL-6 secretion by PBMCs from HS. (D) ELISA assay showing that imoxin
566	

567

#### 568 Figure 6. PKR Inhibitor Imoxin decrease the IL-6 secretion even following viral RNA triggering

- 569 ELISA assay showing that imoxin (C16) significantly decrease the IL-6 secretion in PBMCS from
- 570 HS, even when used 48h after stimulation with poly(I:C).
- 571
- 572